These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28580095)

  • 1. Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV.
    Smith AAA; Zuwala K; Kryger MBL; Wohl BM; Guerrero-Sanchez C; Tolstrup M; Postma A; Zelikin AN
    Chem Sci; 2015 Jan; 6(1):264-269. PubMed ID: 28580095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation.
    Wohl BM; Smith AA; Jensen BE; Zelikin AN
    J Control Release; 2014 Dec; 196():197-207. PubMed ID: 25451544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.
    Riber CF; Hinton TM; Gajda P; Zuwala K; Tolstrup M; Stewart C; Zelikin AN
    Mol Pharm; 2017 Jan; 14(1):234-241. PubMed ID: 28043136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narrow therapeutic window of ribavirin as an inhibitor of nitric oxide synthesis is broadened by macromolecular prodrugs.
    Wohl BM; Smith AA; Kryger MB; Zelikin AN
    Biomacromolecules; 2013 Nov; 14(11):3916-26. PubMed ID: 24156371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.
    Dieterich DT; Purow JM; Rajapaksa R
    Semin Liver Dis; 1999; 19 Suppl 1():87-94. PubMed ID: 10349696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L; Rimola A; Manzardo C; Valdivieso A; Montero JL; Barcena R; Abradelo M; Xiol X; Aguilera V; Salcedo M; Rodriguez M; Bernal C; Suarez F; Antela A; Olivares S; Del Campo S; Laguno M; Fernandez JR; de la Rosa G; Agüero F; Perez I; González-García J; Esteban-Mur JI; Miro JM;
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects.
    Zuwala K; Riber CF; Løvschall KB; Andersen AHF; Sørensen L; Gajda P; Tolstrup M; Zelikin AN
    J Control Release; 2018 Apr; 275():53-66. PubMed ID: 29432822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.
    Ruiz-Sanchis P; Wohl BM; Smith AA; Zuwala K; Melchjorsen J; Tolstrup M; Zelikin AN
    Adv Healthc Mater; 2015 Jan; 4(1):65-8. PubMed ID: 25132665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of HIV and hepatitis virus coinfection.
    Mendes-Corrêa M; Núñez M
    Expert Opin Pharmacother; 2010 Oct; 11(15):2497-516. PubMed ID: 20629586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferon-alpha and ribavirin combination therapy for co-infection of hepatitis C virus and human immunodeficiency virus].
    Zheng YH; He Y; Yang X; Gong GZ; Zhou HY; Zhang CY; Zhou W; Huang L; Ding PP; Li H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Oct; 13(10):741-4. PubMed ID: 16248945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin.
    Hirashima N; Iwase H; Shimada M; Imamura J; Sugiura W; Yokomaku Y; Watanabe T
    Intern Med; 2015; 54(17):2173-7. PubMed ID: 26328642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.
    Ioannou GN; Scott JD; Yang Y; Green PK; Beste LA
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1373-84. PubMed ID: 24127691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
    Naik GS; Tyagi MG
    J Clin Exp Hepatol; 2012 Mar; 2(1):42-54. PubMed ID: 25755405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity.
    Hinton TM; Zuwala K; Deffrasnes C; Todd S; Shi S; Marsh GA; Dearnley M; Wohl BM; Tolstrup M; Zelikin AN
    Adv Healthc Mater; 2016 Mar; 5(5):534-40. PubMed ID: 26789641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.